MDxHealth Reports Strong Q4 Revenue Growth of 28%

MDxHealth SA (MDXH) announces impressive preliminary revenue for Q4 with a growth of 28%. The forecast for 2025 suggests continued momentum, positioning the company favorably in the market.

Date: 13-01-2025

AI Rating: 7

Revenue Growth: The report highlights significant revenue growth for MDxHealth, with an expected $24.7 million for Q4, reflecting a 28% year-over-year increase. For the full-year 2024, revenue is anticipated to be $90 million, also a 28% rise from the previous year. Looking further, revenue projections for 2025 are estimated between $108 million and $110 million, indicating an impressive year-over-year growth of 20% to 22%. This solid revenue trajectory suggests a strong market position and potential investor confidence.

Profitability: The report also mentions that MDxHealth has confirmed the outlook for its first-half adjusted EBITDA profitability. This positive indication of profitability adds to the attractiveness of the company as it suggests effective cost management and operational efficiency.

Considering these outlined growth metrics and profitability guidance, MDxHealth appears to be on a robust growth path. This could lead to increased investor interest and potential upward movement in stock prices as demonstrated by a pre-market increase of 11.11%.

Stocks: MDXH